Literature DB >> 31455869

Mechanisms of lung disease development in rheumatoid arthritis.

Dan Wang1, Jie Zhang2, Jessica Lau3, Shaohua Wang3, Veena Taneja4, Eric L Matteson5, Robert Vassallo6,7.   

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes joint inflammation and damage. Extra-articular manifestations occur in many patients and can include lung involvement in the form of airway or parenchymal inflammation and fibrosis. Although the pathophysiology of articular RA has been extensively investigated, the mechanisms causing airway and parenchymal lung disease are not well defined. Infections, cigarette-smoking, mucosal dysbiosis, host genetics and premature senescence are all potentially important contributors to the development of lung disease in patients with RA. RA-associated lung disease (which can predate the onset of articular disease by many years) probably originates from chronic airway and alveolar epithelial injury that occurs in an individual with a genetic background that permits the development of autoimmunity, leading to chronic inflammation and subsequent airway and lung parenchymal remodelling and fibrosis. Further investigations into the specific mechanisms by which lung disease develops in RA will be crucial for the development of effective therapies. Identifying mechanisms by which environmental and host factors cooperate in the induction of autoimmunity in the lung might also help to establish the order of early events in RA.

Entities:  

Year:  2019        PMID: 31455869     DOI: 10.1038/s41584-019-0275-x

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  21 in total

1.  The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease.

Authors:  Ted R Mikuls; Rohit Gaurav; Geoffrey M Thiele; Bryant R England; Madison G Wolfe; Brianna P Shaw; Kristina L Bailey; Todd A Wyatt; Amy J Nelson; Michael J Duryee; Carlos D Hunter; Dong Wang; Debra J Romberger; Dana P Ascherman; Jill A Poole
Journal:  Int Immunopharmacol       Date:  2021-08-27       Impact factor: 4.932

2.  Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis.

Authors:  Amir A Razmjou; Jennifer M Wang; Ani Shahbazian; Srinivasa Reddy; Christina Charles-Schoeman
Journal:  Clin Rheumatol       Date:  2022-09-22       Impact factor: 3.650

3.  Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients.

Authors:  Marta Novella-Navarro; Alejandro Balsa
Journal:  Drugs Aging       Date:  2022-09-15       Impact factor: 4.271

Review 4.  Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.

Authors:  Elena De Zorzi; Paolo Spagnolo; Elisabetta Cocconcelli; Elisabetta Balestro; Luca Iaccarino; Mariele Gatto; Francesco Benvenuti; Nicol Bernardinello; Andrea Doria; Toby M Maher; Elisabetta Zanatta
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-18       Impact factor: 10.817

5.  Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Authors:  Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Treatm Opt Rheumatol       Date:  2020-09-01

Review 6.  Interstitial lung disease throughout the rheumatoid arthritis disease course.

Authors:  Gregory C McDermott; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

Review 7.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 8.  Inhalants other than personal cigarette smoking and risk for developing rheumatoid arthritis.

Authors:  Lauren C Prisco; Lily W Martin; Jeffrey A Sparks
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

9.  Cathelicidin and Calprotectin Are Disparately Altered in Murine Models of Inflammatory Arthritis and Airway Inflammation.

Authors:  Mahadevappa Hemshekhar; Hadeesha Piyadasa; Dina Mostafa; Leola N Y Chow; Andrew J Halayko; Neeloffer Mookherjee
Journal:  Front Immunol       Date:  2020-08-20       Impact factor: 7.561

Review 10.  Accelerated immunosenescence in rheumatoid arthritis: impact on clinical progression.

Authors:  Moisés E Bauer
Journal:  Immun Ageing       Date:  2020-03-09       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.